At a Glance
- Companies: Benchling and Baseten
- Product: Benchling Inference
- Focus area: AI model training and inference for biotech R&D
- Benefit: Scalable, cost-effective GPU capacity
- Next steps: Roll out to biotech customers
What happened?
Benchling and Baseten have partnered to launch Benchling Inference, a new capability aimed at biotech research and development teams. The product is designed to let customers train and run scientific AI models using scalable GPU capacity without having to manage complex infrastructure.
Why does it matter?
Biotech teams increasingly want to use machine learning on large scientific datasets, but infrastructure can be expensive and difficult to operate. A managed inference layer could lower the technical barrier, making it easier for R&D groups to apply AI to discovery, analysis and decision support.
Who’s behind it?
Benchling is a life sciences R&D platform used by biotech and pharma teams to manage scientific data and workflows. Baseten provides infrastructure for deploying and serving machine learning models, which makes it a natural partner for bringing AI runtime capabilities into Benchling’s ecosystem.
How was it achieved?
Benchling Inference combines Benchling’s scientific data environment with Baseten’s model-serving infrastructure. The goal is to give users access to GPU resources for scientific workloads while abstracting away the complexity of provisioning, scaling and maintaining the underlying compute stack.
What’s next?
The companies will now focus on making the capability available to biotech customers and proving that it can support real R&D use cases at scale. If adoption is strong, the product could become part of a broader shift toward embedded AI infrastructure in life sciences platforms.